Determination of ER in ovarian cancer using monoclonal antibody technology.
The Monoclonal Antibody technology has been used in 29 cases of ovarian cancer. The immuno-enzyme-assay detected positive levels of estrogen cytoplasmatic receptor in 51.8% of the cases as well as in the nuclear (51.8%). Moreover, the ER/EIA technique screened positive levels of Total ER (ER/t) in 72.4% versus 65.5% obtained by DCC-method. 24.1% of the cases had negative ER/t levels observed by EIA. The monoclonal antibody anti-ER is a very interesting method for studying hormone-dependent tissue, because it uses an immunological binding to antigenic protein (receptor).
Nardelli
G B
GB
Institute of Obstetrics and Gynaecology, University of Padua, Italy.
Lamaina
V
V
Dal Pozzo
M
M
Onnis
G L
GL
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D002467:Cell Nucleus / Q000648:ultrastructure; D003593:Cytoplasm / Q000648:ultrastructure; D003600:Cytosol / Q000648:ultrastructure; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000473:pathology*; D010053:Ovary / Q000473:pathology; D011960:Receptors, Estrogen / Q000032:analysis*
D000911:Antibodies, Monoclonal; D011960:Receptors, Estrogen